Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Lumos Pharma Inc (LUMO)

Lumos Pharma Inc (LUMO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 37,448
  • Shares Outstanding, K 8,649
  • Annual Sales, $ 2,050 K
  • Annual Income, $ -34,030 K
  • EBIT $ -36 M
  • EBITDA $ -36 M
  • 60-Month Beta 0.76
  • Price/Sales 18.22
  • Price/Cash Flow N/A
  • Price/Book 7.16

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.38
  • Number of Estimates 2
  • High Estimate 0.22
  • Low Estimate -0.97
  • Prior Year -1.17
  • Growth Rate Est. (year over year) +67.52%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.92 +10.46%
on 10/22/24
4.58 -5.37%
on 10/23/24
+0.60 (+16.08%)
since 10/21/24
3-Month
2.92 +48.03%
on 08/22/24
4.58 -5.37%
on 10/23/24
+1.34 (+44.82%)
since 08/21/24
52-Week
1.37 +216.04%
on 07/10/24
4.58 -5.37%
on 10/23/24
+1.28 (+41.97%)
since 11/21/23

Most Recent Stories

More News
Lumos Pharma Presents New Data on LUM-201 from Phase 2 Trials for Pediatric Growth Hormone Deficiency at ESPE 2024

Lumos Pharma presented positive Phase 2 trial data for oral LUM-201, showing sustained growth in pediatric patients with hormone deficiency.Quiver AI SummaryLumos Pharma, Inc. has presented new analyses...

LUMO : 4.33 (+0.23%)
Updated Phase 2 OraGrowtH Data Presented at ESPE 2024 Demonstrate Sustained Growth on Oral LUM-201 to 24 Months in PGHD and Correlation of Growth to LUM-201’s Unique Pulsatile Mechanism of Action

LUMO : 4.33 (+0.23%)
Lumos: Q3 Earnings Snapshot

Lumos: Q3 Earnings Snapshot

LUMO : 4.33 (+0.23%)
Lumos Pharma Announces Two Abstracts Accepted for Oral Presentation at the 62ⁿᵈ Annual ESPE Meeting 2024

LUMO : 4.33 (+0.23%)
Lumos Pharma Enters into Definitive Merger Agreement with Double Point Ventures to Go Private via a Tender Offer of $4.25 Cash per Share Plus Contingent Value Rights (CVR)

LUMO : 4.33 (+0.23%)
Lumos: Q2 Earnings Snapshot

Lumos: Q2 Earnings Snapshot

LUMO : 4.33 (+0.23%)
Lumos Pharma Reports Second Quarter 2022 Financial Results and Clinical Development Updates

-- Continue to Anticipate Interim Data from Phase 2 OraGrowtH210 and PK/PD OraGrowtH212 Trials in Q4 2022 -- -- Primary Outcome Readouts from Both Trials...

LUMO : 4.33 (+0.23%)
Lumos Pharma to Report Second Quarter 2022 Financial Results and Host Conference Call on August 9, 2022

AUSTIN, Texas, July 27, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company, today announced it will...

LUMO : 4.33 (+0.23%)
Lumos Pharma to Participate in Upcoming Investor Conferences

AUSTIN, Texas, May 16, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for...

LUMO : 4.33 (+0.23%)
Lumos Pharma Reports First Quarter 2022 Financial Results and Clinical Development Updates

--Phase 2 OraGrowtH210 Trial Reached 50% Randomization Milestone – Interim Data from Phase 2 and PK/PD OraGrowtH Trials Anticipated by End of 2022-- --FDA...

LUMO : 4.33 (+0.23%)

Business Summary

Lumos Pharma Inc. is a clinical stage biopharmaceutical company. It is focused on the development and commercialization of therapeutics for rare and neglected diseases. The company's product pipeline consists of LUM-201 which is in clinical stage. Lumos Pharma Inc., formerly known as NewLink Genetics...

See More

Key Turning Points

3rd Resistance Point 4.44
2nd Resistance Point 4.41
1st Resistance Point 4.37
Last Price 4.33
1st Support Level 4.30
2nd Support Level 4.27
3rd Support Level 4.23

See More

52-Week High 4.58
Last Price 4.33
Fibonacci 61.8% 3.35
Fibonacci 50% 2.97
Fibonacci 38.2% 2.59
52-Week Low 1.37

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar